To evaluate the efficacy of ralizumab combined with Traditional Chinese medicine in the treatment of macular edema secondary to retinal vein occlusion based on a real-world study
Phase 1
Not yet recruiting
- Conditions
- retinal vein occlusion
- Registration Number
- ITMCTR2200005968
- Lead Sponsor
- Shenzhen Traditional Chinese Medicine Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
18-80 years old RVO secondary macular edema, TCM syndromes conform to spleen deficiency phlegm-dampness type
Exclusion Criteria
1. RVO patients are younger than 18 years old or older than 80 years old;
2. TCM syndromes of RVO patients do not conform to the type of spleen deficiency and phlegm-dampness;
3. RVO patients have severe proliferative retinopathy or retinal detachment;
4. Patients with RVO receive systemic or local (vitreous injection) hormones.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie ralizumab's anti-VEGF effects in retinal vein occlusion macular edema?
How does Wenyang Jianpi Lishi Prescription compare to standard anti-VEGF monotherapy for retinal vein occlusion?
Which biomarkers correlate with response to TCM-based combination therapy in retinal vein occlusion patients?
What adverse events are associated with ralizumab and traditional Chinese medicine in macular edema treatment?
Are there alternative anti-VEGF combination therapies for spleen deficiency phlegm-dampness related retinal vein occlusion?